{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:51:04Z","timestamp":1793317864544,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T00:00:00Z","timestamp":1595548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta (OI) is a chronic disease with few treatment options available. The purpose of this review is to provide an overview on treating OI with mesenchymal stem cells (MSC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Off-the-shelf MSC have a good safety profile and exhibit multilineage differentiation potential and a low immunogenic profile and are easy to manufacture. Their ability to migrate, engraft, and differentiate into bone cells, and also to act via paracrine effects on the recipient\u2019s tissues, makes MSC candidates as a clinical therapy for OI. Due to their high osteogenic potency, fetal MSC offer an even higher therapeutic potential in OI compared with MSC derived from adult sources. Preclinical and initial clinical data support the use of MSC in treating OI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>The characteristics of MSC make them of great interest in treating OI. MSC may be safely transplanted via intravenous administration and show potential positive clinical effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11914-020-00594-3","type":"journal-article","created":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T02:02:43Z","timestamp":1595556163000},"page":"337-343","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Stem Cell Therapy as a Treatment for Osteogenesis Imperfecta"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3782-0048","authenticated-orcid":false,"given":"Cecilia","family":"G\u00f6therstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Walther-Jallow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,24]]},"reference":[{"issue":"1","key":"594_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","volume":"14","author":"IH Thomas","year":"2016","unstructured":"Thomas IH, DiMeglio LA. Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep. 2016;14(1):1\u20139. https:\/\/doi.org\/10.1007\/s11914-016-0299-y.","journal-title":"Curr Osteoporos Rep"},{"key":"594_CR2","doi-asserted-by":"publisher","first-page":"17052","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, Bachinger HP, Bishop NJ, Byers PH, Paepe A, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3:17052. https:\/\/doi.org\/10.1038\/nrdp.2017.52.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"594_CR3","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/jbmr.2895","volume":"31","author":"L Folkestad","year":"2016","unstructured":"Folkestad L, Hald JD, Canudas-Romo V, Gram J, Hermann AP, Langdahl B, et al. Mortality and causes of death in patients with osteogenesis imperfecta: a register-based nationwide cohort study. J Bone Miner Res. 2016;31(12):2159\u201366. https:\/\/doi.org\/10.1002\/jbmr.2895.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"594_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet. 1979;16(2):101\u201316.","journal-title":"J Med Genet"},{"issue":"3","key":"594_CR5","first-page":"813","volume":"96","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Horton WA, Rimoin DL. Morphologic studies in the skeletal dysplasias. Am J Pathol. 1979;96(3):813\u201370.","journal-title":"Am J Pathol"},{"issue":"9418","key":"594_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet. 2004;363(9418):1377\u201385.","journal-title":"Lancet."},{"issue":"3","key":"594_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/ng1968","volume":"39","author":"WA Cabral","year":"2007","unstructured":"Cabral WA, Chang W, Barnes AM, Weis M, Scott MA, Leikin S, et al. Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta. Nat Genet. 2007;39(3):359\u201365. https:\/\/doi.org\/10.1038\/ng1968.","journal-title":"Nat Genet"},{"issue":"1","key":"594_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejmg.2009.10.007","volume":"53","author":"FS Van Dijk","year":"2010","unstructured":"Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM. Classification of osteogenesis imperfecta revisited. Eur J Med Genet. 2010;53(1):1\u20135. https:\/\/doi.org\/10.1016\/j.ejmg.2009.10.007.","journal-title":"Eur J Med Genet"},{"issue":"10","key":"594_CR9","doi-asserted-by":"publisher","first-page":"e10216","DOI":"10.1002\/jbm4.10216","volume":"3","author":"CS Constantino","year":"2019","unstructured":"Constantino CS, Krzak JJ, Fial AV, Kruger KM, Rammer JR, Radmanovic K, et al. Effect of bisphosphonates on function and mobility among children with osteogenesis imperfecta: a systematic review. JBMR Plus. 2019;3(10):e10216. https:\/\/doi.org\/10.1002\/jbm4.10216.","journal-title":"JBMR Plus"},{"issue":"5411","key":"594_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1126\/science.284.5411.143","volume":"284","author":"MF Pittenger","year":"1999","unstructured":"Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284(5411):143\u20137.","journal-title":"Science."},{"issue":"11","key":"594_CR11","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1038\/81395","volume":"6","author":"KW Liechty","year":"2000","unstructured":"Liechty KW, MacKenzie TC, Shaaban AF, Radu A, Moseley AM, Deans R, et al. Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med. 2000;6(11):1282\u20136.","journal-title":"Nat Med"},{"issue":"8","key":"594_CR12","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1182\/blood-2002-06-1830","volume":"101","author":"SM Devine","year":"2003","unstructured":"Devine SM, Cobbs C, Jennings M, Bartholomew A, Hoffman R. Mesenchymal stem cells distribute to a wide range of tissues following systemic infusion into nonhuman primates. Blood. 2003;101(8):2999\u20133001.","journal-title":"Blood."},{"issue":"4","key":"594_CR13","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1634\/stemcells.2006-0694","volume":"25","author":"J Chan","year":"2007","unstructured":"Chan J, Waddington SN, O'Donoghue K, Kurata H, Guillot PV, G\u00f6therstr\u00f6m C, et al. Widespread distribution and muscle differentiation of human fetal mesenchymal stem cells after intrauterine transplantation in dystrophic mdx mouse. Stem Cells. 2007;25(4):875\u201384. https:\/\/doi.org\/10.1634\/stemcells.2006-0694.","journal-title":"Stem Cells"},{"issue":"5","key":"594_CR14","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/path.2325","volume":"214","author":"PV Guillot","year":"2008","unstructured":"Guillot PV, Cook HT, Pusey CD, Fisk NM, Harten S, Moss J, et al. Transplantation of human fetal mesenchymal stem cells improves glomerulopathy in a collagen type I alpha 2-deficient mouse. J Pathol. 2008;214(5):627\u201336. https:\/\/doi.org\/10.1002\/path.2325.","journal-title":"J Pathol"},{"issue":"8","key":"594_CR15","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1089\/hum.2015.072","volume":"26","author":"N Heldring","year":"2015","unstructured":"Heldring N, Mager I, Wood MJ, Le Blanc K, Andaloussi SE. Therapeutic potential of multipotent mesenchymal stromal cells and their extracellular vesicles. Hum Gene Ther. 2015;26(8):506\u201317. https:\/\/doi.org\/10.1089\/hum.2015.072.","journal-title":"Hum Gene Ther"},{"key":"594_CR16","doi-asserted-by":"publisher","unstructured":"Colombini A, Perucca Orfei C, Kouroupis D, Ragni E, De Luca P, Vigan OM, et al. Mesenchymal stem cells in the treatment of articular cartilage degeneration: new biological insights for an old-timer cell. Cytotherapy. 2019. https:\/\/doi.org\/10.1016\/j.jcyt.2019.10.004.","DOI":"10.1016\/j.jcyt.2019.10.004"},{"issue":"1","key":"594_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40778-018-0118-8","volume":"4","author":"R Sagar","year":"2018","unstructured":"Sagar R, Walther-Jallow L, David AL, G\u00f6therstr\u00f6m C, Westgren M. Fetal mesenchymal stromal cells: an opportunity for prenatal cellular therapy. Curr Stem Cell Rep. 2018;4(1):61\u20138. https:\/\/doi.org\/10.1007\/s40778-018-0118-8.","journal-title":"Curr Stem Cell Rep"},{"issue":"3","key":"594_CR18","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1634\/stemcells.2006-0208","volume":"25","author":"PV Guillot","year":"2007","unstructured":"Guillot PV, G\u00f6therstr\u00f6m C, Chan J, Kurata H, Fisk NM. Human first-trimester fetal MSC express pluripotency markers and grow faster and have longer telomeres than adult MSC. Stem Cells. 2007;25(3):646\u201354. https:\/\/doi.org\/10.1634\/stemcells.2006-0208.","journal-title":"Stem Cells"},{"issue":"1","key":"594_CR19","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1634\/stemcells.2008-0456","volume":"27","author":"ZY Zhang","year":"2009","unstructured":"Zhang ZY, Teoh SH, Chong MS, Schantz JT, Fisk NM, Choolani MA, et al. Superior osteogenic capacity for bone tissue engineering of fetal compared with perinatal and adult mesenchymal stem cells. Stem Cells. 2009;27(1):126\u201337. https:\/\/doi.org\/10.1634\/stemcells.2008-0456.","journal-title":"Stem Cells"},{"issue":"8","key":"594_CR20","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1634\/stemcells.2005-0564","volume":"24","author":"J Chan","year":"2006","unstructured":"Chan J, O'Donoghue K, Gavina M, Torrente Y, Kennea N, Mehmet H, et al. Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. Stem Cells. 2006;24(8):1879\u201391. https:\/\/doi.org\/10.1634\/stemcells.2005-0564.","journal-title":"Stem Cells"},{"issue":"5 Suppl","key":"594_CR21","first-page":"S11","volume":"32","author":"J Chan","year":"2003","unstructured":"Chan J, O'Donoghue K, Kennea N, de la Fuente J, Kumar S, Morgan J, et al. Myogenic potential of fetal mesenchymal stem cells. Ann Acad Med Singapore. 2003;32(5 Suppl):S11\u20133.","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"594_CR22","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.juro.2006.09.103","volume":"177","author":"P De Coppi","year":"2007","unstructured":"De Coppi P, Callegari A, Chiavegato A, Gasparotto L, Piccoli M, Taiani J, et al. Amniotic fluid and bone marrow derived mesenchymal stem cells can be converted to smooth muscle cells in the cryo-injured rat bladder and prevent compensatory hypertrophy of surviving smooth muscle cells. J Urol. 2007;177(1):369\u201376. https:\/\/doi.org\/10.1016\/j.juro.2006.09.103.","journal-title":"J Urol"},{"issue":"7","key":"594_CR23","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.4161\/cc.8.7.8121","volume":"8","author":"NL Kennea","year":"2009","unstructured":"Kennea NL, Waddington SN, Chan J, O'Donoghue K, Yeung D, Taylor DL, et al. Differentiation of human fetal mesenchymal stem cells into cells with an oligodendrocyte phenotype. Cell Cycle. 2009;8(7):1069\u201379.","journal-title":"Cell Cycle"},{"issue":"9","key":"594_CR24","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/j.1432-0436.2008.00279.x","volume":"76","author":"PV Guillot","year":"2008","unstructured":"Guillot PV, De Bari C, Dell'Accio F, Kurata H, Polak J, Fisk NM. Comparative osteogenic transcription profiling of various fetal and adult mesenchymal stem cell sources. Differentiation. 2008;76(9):946\u201357. https:\/\/doi.org\/10.1111\/j.1432-0436.2008.00279.x.","journal-title":"Differentiation."},{"key":"594_CR25","doi-asserted-by":"publisher","unstructured":"Zhang ZY, Teoh SH, Chong MS, Lee ES, Tan LG, Mattar CN, et al. Neo-vascularization and bone formation mediated by fetal mesenchymal stem cell tissue-engineered bone grafts in critical-size femoral defects. Biomaterials. 2010. https:\/\/doi.org\/10.1016\/j.biomaterials.2009.09.078.","DOI":"10.1016\/j.biomaterials.2009.09.078"},{"issue":"10","key":"594_CR26","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/S0301-472X(03)00110-3","volume":"31","author":"K Le Blanc","year":"2003","unstructured":"Le Blanc K, Tammik L, Zetterberg E, Ringd\u00e9n O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol. 2003;31(10):890\u20136.","journal-title":"Exp Hematol"},{"issue":"1","key":"594_CR27","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.ajog.2003.07.022","volume":"190","author":"C G\u00f6therstr\u00f6m","year":"2004","unstructured":"G\u00f6therstr\u00f6m C, Ringden O, Tammik C, Zetterberg E, Westgren M, Le Blanc K. Immunologic properties of human fetal mesenchymal stem cells. Am J Obstet Gynecol. 2004;190(1):239\u201345.","journal-title":"Am J Obstet Gynecol"},{"issue":"3","key":"594_CR28","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3109\/14653249.2010.523077","volume":"13","author":"C G\u00f6therstr\u00f6m","year":"2011","unstructured":"G\u00f6therstr\u00f6m C, Lundqvist A, Duprez IR, Childs R, Berg L, le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy. 2011;13(3):269\u201378. https:\/\/doi.org\/10.3109\/14653249.2010.523077.","journal-title":"Cytotherapy."},{"issue":"3","key":"594_CR29","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/sj.bmt.1704111","volume":"32","author":"C G\u00f6therstr\u00f6m","year":"2003","unstructured":"G\u00f6therstr\u00f6m C, Ringden O, Westgren M, Tammik C, Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant. 2003;32(3):265\u201372.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"594_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1046\/j.1365-3083.2003.01176.x","volume":"57","author":"K Le Blanc","year":"2003","unstructured":"Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol. 2003;57(1):11\u201320.","journal-title":"Scand J Immunol"},{"issue":"3","key":"594_CR31","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1073\/pnas.95.3.1142","volume":"95","author":"RF Pereira","year":"1998","unstructured":"Pereira RF, O'Hara MD, Laptev AV, Halford KW, Pollard MD, Class R, et al. Marrow stromal cells as a source of progenitor cells for nonhematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta. Proc Natl Acad Sci U S A. 1998;95(3):1142\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"594_CR32","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood-2008-12-195859","volume":"114","author":"C Panaroni","year":"2009","unstructured":"Panaroni C, Gioia R, Lupi A, Besio R, Goldstein SA, Kreider J, et al. In utero transplantation of adult bone marrow decreases perinatal lethality and rescues the bone phenotype in the knockin murine model for classical, dominant osteogenesis imperfecta. Blood. 2009;114(2):459\u201368. https:\/\/doi.org\/10.1182\/blood-2008-12-195859.","journal-title":"Blood."},{"issue":"3","key":"594_CR33","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1182\/blood-2007-08-105809","volume":"111","author":"PV Guillot","year":"2008","unstructured":"Guillot PV, Abass O, Bassett JH, Shefelbine SJ, Bou-Gharios G, Chan J, et al. Intrauterine transplantation of human fetal mesenchymal stem cells from first-trimester blood repairs bone and reduces fractures in osteogenesis imperfecta mice. Blood. 2008;111(3):1717\u201325. https:\/\/doi.org\/10.1182\/blood-2007-08-105809.","journal-title":"Blood."},{"issue":"3","key":"594_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1182\/blood-2010-05-287565","volume":"117","author":"M Vanleene","year":"2011","unstructured":"Vanleene M, Saldanha Z, Cloyd KL, Jell G, Bou-Gharios G, Bassett JH, et al. Transplantation of human fetal blood stem cells in the osteogenesis imperfecta mouse leads to improvement in multiscale tissue properties. Blood. 2011;117(3):1053\u201360. https:\/\/doi.org\/10.1182\/blood-2010-05-287565.","journal-title":"Blood."},{"issue":"3","key":"594_CR35","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1089\/scd.2013.0132","volume":"23","author":"GN Jones","year":"2014","unstructured":"Jones GN, Moschidou D, Abdulrazzak H, Kalirai BS, Vanleene M, Osatis S, et al. Potential of human fetal chorionic stem cells for the treatment of osteogenesis imperfecta. Stem Cells Dev. 2014;23(3):262\u201376. https:\/\/doi.org\/10.1089\/scd.2013.0132.","journal-title":"Stem Cells Dev"},{"issue":"10","key":"594_CR36","doi-asserted-by":"publisher","first-page":"e47559","DOI":"10.1371\/journal.pone.0047559","volume":"7","author":"MM Lalu","year":"2012","unstructured":"Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials. PLoS One. 2012;7(10):e47559. https:\/\/doi.org\/10.1371\/journal.pone.0047559.","journal-title":"PLoS One"},{"issue":"5","key":"594_CR37","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3727\/096368915X689622","volume":"25","author":"T Squillaro","year":"2016","unstructured":"\u2022\u2022 Squillaro T, Peluso G, Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant. 2016;25(5):829\u201348. https:\/\/doi.org\/10.3727\/096368915X689622. The paper summarizes the recent progress in the MSC therapy field.","journal-title":"Cell Transplant"},{"issue":"2","key":"594_CR38","doi-asserted-by":"publisher","first-page":"539","DOI":"10.5966\/sctm.2015-0427","volume":"6","author":"CR Nitkin","year":"2017","unstructured":"\u2022\u2022 Nitkin CR, Bonfield TL. Concise review: mesenchymal stem cell therapy for pediatric disease: perspectives on success and potential improvements. Stem Cells Transl Med. 2017;6(2):539\u201365. https:\/\/doi.org\/10.5966\/sctm.2015-0427. The paper summarizes the recent progress in the MSC therapy field in the pediatric population.","journal-title":"Stem Cells Transl Med"},{"issue":"5","key":"594_CR39","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1182\/blood.V97.5.1227","volume":"97","author":"EM Horwitz","year":"2001","unstructured":"Horwitz EM, Prockop DJ, Gordon PL, Koo WW, Fitzpatrick LA, Neel MD, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood. 2001;97(5):1227\u201331.","journal-title":"Blood."},{"issue":"13","key":"594_CR40","doi-asserted-by":"publisher","first-page":"8932","DOI":"10.1073\/pnas.132252399","volume":"99","author":"EM Horwitz","year":"2002","unstructured":"Horwitz EM, Gordon PL, Koo WK, Marx JC, Neel MD, McNall RY, et al. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci U S A. 2002;99(13):8932\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"594_CR41","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1097\/01.TP.0000159029.48678.93","volume":"79","author":"K Le Blanc","year":"2005","unstructured":"Le Blanc K, G\u00f6therstr\u00f6m C, Ringden O, Hassan M, McMahon R, Horwitz E, et al. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation. 2005;79(11):1607\u201314.","journal-title":"Transplantation."},{"issue":"2","key":"594_CR42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.5966\/sctm.2013-0090","volume":"3","author":"C G\u00f6therstr\u00f6m","year":"2014","unstructured":"\u2022\u2022 G\u00f6therstr\u00f6m C, Westgren M, Shaw SW, \u00c5str\u00f6m E, Biswas A, Byers PH, et al. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med. 2014;3(2):255\u201364. https:\/\/doi.org\/10.5966\/sctm.2013-0090. The paper describes the two first prenatal fetal MSC transplantations as treatment of OI, which resulted in donor cell engraftment in bone and potential clinical effects.","journal-title":"Stem Cells Transl Med"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00594-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11914-020-00594-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00594-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,23]],"date-time":"2021-07-23T20:10:27Z","timestamp":1627071027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11914-020-00594-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,24]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["594"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00594-3","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,24]]},"assertion":[{"value":"24 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}